Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Elongin C pseudogene 23 (ELOCP23), also known as TCEB1P23, is classified as a pseudogene in the human genome[3][5]. Pseudogenes are genomic sequences similar to known genes but are non-functional due to mutations or lack of regulatory elements, meaning they do not encode a functional protein product. ELOCP23 does not produce the elongin C protein and is not associated with any known biological functions, disease roles, or drug interactions[3][5]. This distinguishes it from the functional ELOC (Elongin C) gene, which is a critical component of the transcription factor B (SIII) complex involved in transcription elongation by RNA polymerase II[1][2], but ELOCP23 itself has no known functional role.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Elongin C pseudogene 23 (ELOCP23).